Objectives: The efficacy of sofosbuvir plus ribavirin (RBV) treatment for hepatitis C virus (HCV) genotype 2 focusing on virological response was compared with that of pegylated interferon (peg-IFN) plus RBV treatment. Safety of the former focusing on the decline in hemoglobin levels was compared with that of the latter and assessed in terms of age and inosine triphosphatase (ITPA).

Methods: Patients (n = 17) receiving sofosbuvir plus RBV and those (n = 24) receiving peg-IFN plus RBV diagnosed with chronic HCV genotype 2 were enrolled in this study, and the efficacy and safety of both treatments were assessed.

Results: Rapid virological response was attained with sofosbuvir plus RBV treatment compared with peg-IFN plus RBV treatment. All patients under sofosbuvir plus RBV treatment achieved end-of-treatment response compared with 70% who sustained viral response under the peg-IFN plus RBV treatment, with the former demonstrating greater virological response. The decline in hemoglobin levels under the former treatment was greater than that under the latter and in patients over 65 years of age with ITPA gene major.

Conclusion: Efficacy and safety of sofosbuvir plus RBV treatment were clearly demonstrated compared with those of peg-IFN plus RBV treatment. The decline in hemoglobin levels was not related to the discontinuation of the former treatment, irrespective of age or the effect of the ITPA gene.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000448823DOI Listing

Publication Analysis

Top Keywords

rbv treatment
32
peg-ifn rbv
20
sofosbuvir rbv
16
efficacy safety
12
virological response
12
decline hemoglobin
12
hemoglobin levels
12
treatment
11
rbv
10
safety sofosbuvir
8

Similar Publications

Peroxidized lipids have been shown to reduce broiler performance whereupon it was theorized that dietary peroxide value (PV) plus anisidine value (AnV) may be predictive of broiler performance. In experiment (EXP) 1, 64 pens (8 broilers/pen) were fed diets containing 8 levels of peroxidized soybean oil (SO). Broilers were fed diets from 7 to 35 d of age with 8 replications per dietary treatment.

View Article and Find Full Text PDF

Background: Hepatitis C virus (HCV) eradication with sofosbuvir/velpatasvir (SOF/VEL) represents a significant advancement, offering hope for eliminating the virus in diverse patient populations. But real-world data on its effectiveness and safety remains scarce for patients with chronic hepatitis C (CHC) in China, especially those with HCV GT3b, cirrhosis, hepato-cellular carcinoma (HCC), or HCV/hepatitis B (HBV), HCV/HIV, or HCV/HBV/HIV coinfection.

Methods: In this real-world prospective observational study, we recruited patients from the West China Hospital and Public Health Clinical Center of Chengdu in China.

View Article and Find Full Text PDF

The calculation of the relative bioavailability (RBV) of rumen-protected AA supplements using the plasma free AA dose-response technique currently relies on blood samples obtained 2, 4, 6, and 8 h after the 0500 h feeding during the last 3 d of each period in Latin square experiments with cows fed every 8 h (0500, 1300, and 2100 h). The objective of this study was to determine if this current blood sampling protocol captures the changes that may occur in plasma Met concentrations within a 24-h day to adequately determine the RBV of Met from Smartamine M (SM). Five multiparous lactating Holstein cows were used in a 5 × 5 Latin square design with 7-d periods.

View Article and Find Full Text PDF

Background: Among inherited cardiomyopathies involving the left ventricle, whether dilated or not, certain genotypes carry a well-established arrhythmic risk, notably manifested as sustained monomorphic ventricular tachycardia (SMVT). Nonetheless, the precise localization and electrophysiological profile of this substrate remain undisclosed across different genotypes.

Methods: Patients diagnosed with cardiomyopathy and left ventricle involvement due to high-risk genetic variants and SMVT treated by electrophysiological study were recruited from 18 European/US centers.

View Article and Find Full Text PDF

Direct-acting antivirals (DAA) are effective in patients with hepatitis C virus (HCV) infection, but there is little information about real-world effectiveness in people living with human immunodeficiency virus (PLH). The aim of this study was to determinate the effectiveness of DAA to achieve sustained virologic response at week 12 post-treatment (SVR12) in PLH with HCV coinfection and in people with HCV-monoinfection. We conducted a prospective cohort.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!